Company Overview
Company Type: Private Company
Website: www.purminds.com
Number of Employees: -
Year Founded: 2020
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
PurMinds NeuroPharma Inc. engages in drug discovery for neurodegenerative diseases. It offers PurPrecision, a neuromedicine development platform to analyze iPSC-derived neurons from neurodegenerative diseased patients and non-neurological healthy controls using multi-omics and network-based integrative computational analyses; data informed pipeline; PurMinds NeuroLab, in-house screening technologies, analytical testing capabilities, and other research and production capabilities. The company was founded in 2020 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
No Key Professionals have been profiled.


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
1 Concorde Gate Suite 604 | Toronto, ON | M3C 3N6 | Canada


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
IMIO Life Ltd.
IMIO Life Ltd., a psychedelic drug company, focuses on developing psychedelic-based therapeutics. The company is based in Ness Ziona, Israel. IMIO Life Ltd. operates as a subsidiary of Nextage Therapeutics Ltd.

Africa / Middle East
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-13-2021
Jul-06-2021
Private Placement
Buyer
IMIO Life Ltd.
PurMinds NeuroPharma Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-09-2023
Company Conference Presentations
PurMinds NeuroPharma Inc. Presents at Biotech Showcase 2023, Jan-09-2023
Nov-08-2021
Company Conference Presentations
PurMinds BioPharma Inc. Presents at Wonderland: Miami conference, Nov-08-2021
Jul-06-2021
Private Placements
IMIO Life Ltd. announced that it has received funding from PurMinds BioPharma Inc.
Jun-13-2021
Private Placements
IMIO Life Ltd. announced that it expects to receive funding from PurMinds BioPharma Inc.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 11:28 PM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Sep 14, 2023 08:31 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc
Reports
26
GlobalData

Jun 29, 2023 01:24 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc
Reports
25
GlobalData

Jun 09, 2023 03:02 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
16
GlobalData

Mar 14, 2023 02:34 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc
Reports
25
GlobalData

Mar 10, 2023 06:03 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
16
GlobalData

Dec 16, 2022 01:10 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc
Reports
25
GlobalData

Dec 10, 2022 03:48 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
16
GlobalData

Sep 20, 2022 08:08 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc
Reports
25
GlobalData

Sep 15, 2022 05:12 AM
PurMinds NeuroPharma Inc.
PurMinds NeuroPharma Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
No Key Executives and Professionals exist.

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
